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What is the key question? 
Are there international disparities in lung cancer survival by clinically-relevant subgroups in the 
most recent population level data?   
 
What is the bottom line? 
International differences in survival among patients with lung cancer persist in high-income 
countries, which are partly due to differences in stage at diagnosis or early detection, and to 
survival difference within stage groups due to cancer management. 
 
Why read on? 
This study presents in-depth results of the most-up-to-date differences of lung cancer stage 
distribution and survival by histological types, age group and sex for each included country, as 
well as within countries, followed by a discussion of potential causes of the disparities including 








Introduction: Lung cancer has a poor prognosis that varies internationally when assessed by the 
two major histological subgroups [non-small cell (NSCLC) and small cell (SCLC)]. 
Method: 236,114 NSCLC and 43,167 SCLC cases diagnosed during 2010-2014 in Australia, 
Canada, Denmark, Ireland, New Zealand, Norway, and the United Kingdom (UK) were included 
in the analyses. One- and 3-year age-standardised net survival (NS) was estimated by sex, 
histological type, stage, and country.  
Results: One- and 3-year NS was consistently higher for Canada and Norway, and lower for the 
UK, New Zealand and Ireland, irrespective of stage at diagnosis. Three-year NS for NSCLC 
ranged from 19.7% for the UK to 27.1% for Canada for males and was consistently higher for 
females (25.3% in the UK; 35.0% in Canada) partly because males were diagnosed at more 
advanced stages. International differences in survival for NSCLC were largest for regional stage 
and smallest at the advanced stage. For SCLC, 3-year NS also showed a clear female advantage 
with the highest being for Canada (13.8% for females; 9.1% for males) and Norway (12.8% for 
females; 9.7% for males).  
Conclusion: Distribution of stage at diagnosis among lung cancer cases differed by sex, 
histological subtype and country, which may partly explain observed survival differences. Yet, 
survival differences were also observed within stages, suggesting that quality of treatment, 
healthcare system factors, and prevalence of comorbid conditions may also influence survival. 
Other possible explanations include differences in data collection practice, as well as differences 
in histological verification, staging and coding across jurisdictions. 




Lung cancer is the leading cause of cancer death among men and women worldwide, with an 
estimated 1.6 million deaths, or nearly 20% of all cancer deaths, occurring in 2018.1 Lung cancer 
is categorised into two main histological groups - small cell lung carcinoma (SCLC) and non-small 
cell lung carcinoma (NSCLC) - with SCLC patients generally having poorer outcomes compared 
to NSCLC.2 Marked sex differences in survival have also been previously reported, with females 
having a more favourable prognosis.3-6  
 
As cancer survival is one of the key measures of performance improvement in health care, 
international cancer survival comparisons can identify possible causes for observed variations, 
such as access to early detection or optimal treatments. The International Cancer Benchmarking 
Partnership (ICBP), a consortium of clinicians, policy-makers, researchers, and cancer data 
experts, has previously described lung cancer survival differences across high-income countries7 
and concluded that stage at diagnosis and histological type explained some of the international 
variation in lung cancer survival in 2004-2007.2 In this study, we extend this prior work by 
assessing the most up-to-date lung cancer survival statistics by sex and stage at diagnosis for 




Data were collected as part of the ICBP SURVMARK-2 project for patients diagnosed during 
1995-2014 at ages above 18 years and followed until the end of 2015.8 ICBP countries were 
included due to their high-quality population-wide registries, universal access to healthcare with 
similar healthcare expenditure, and interest in understanding how and why cancer survival differs 
across countries. For this study, lung carcinoma data from 18 population-based cancer registries 
in seven countries with at least 50% complete data on stage at diagnosis during 2010-2014, were 
included (Australia - New South Wales; Canada - Alberta, British Columbia, Manitoba, New 
Brunswick, Newfoundland, Nova Scotia, Ontario, Prince Edward Island, Saskatchewan; 
Denmark; Ireland (2010-2013); New Zealand; Norway; and the UK - England, Scotland, Wales, 
Northern Ireland). Cases diagnosed with an invasive primary malignant tumour of the lung and 
bronchus (ICD-10: C34) were classified as SCLC, NSCLC, other and unspecified histology (see 
Table 1). Of 393,453 adult lung cancer patients diagnosed during 2010-2014, we excluded cases 
diagnosed based on death certificate only (DCO) or at autopsy (N=8,105, 2.1%), with inconsistent 
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dates (N=54, <0.0%), below age 15 or above age 99 (N=127, <0.0%), with second primary cancer 
in the lung (N=5,034, 1.3%), with incorrect stage information (N=4,557, 1.2%) or classified as 
neuroendocrine neoplasms (NEN) (N=7,869, 2.0%).  
 
Each participating cancer registry provided information on pre-treatment pathological and clinical 
stage based on the tumour extent (T), the degree of nodal involvement (N), and the presence of 
metastases (M), grouped TNM (stages I-IV), and SEER summary stage 2000 (Supplementary 
Figure 1A). A previously developed algorithm9 was adapted to harmonise individual or grouped 
TNM information (7th edition10) to SEER stage (localised, regional, distant and missing), creating 
a ‘mapped SEER stage’ that combines both TNM and SEER stage information; during the stage 
mapping, pathological T and N, and clinical M information was prioritised if both pathological and 
clinical data were available (Supplementary Figure 1B).  
 
Statistical analyses 
We estimated net survival, which is the survival of cancer patients after adjustments for 
background mortality in the general population using life tables. Life tables were specific to sex, 
single year of age, geographical region and year of death. Net survival estimates at one and three 
years after diagnosis were estimated by histological group and sex for each country and 
jurisdiction, as appropriate, using Pohar Perme estimators.11 Age-standardisation was carried out 
using International Cancer Survival Standard weights.12 The period approach was used to provide 
short-term predictions of three-year survival for patients diagnosed during 2010-2014. Statistically 
significant differences in net survival between sexes, histological subgroups, countries or 
jurisdictions were determined by comparing the 95% confidence intervals (95%CI). 
 
Stage at diagnosis was imputed separately for SCLC and NSCLC patients with missing stage 
data (SCLC missingness range:  1.1% (Denmark – SEER) to 33.6% (UK – TNM); NSCLC missing 
range: 1.1% (Denmark –SEER) to 33.3% (UK – TNM). Covariates in the imputation model 
included age, sex, year of diagnosis, survival time, and the Nelson-Aalen estimator of the 
cumulative hazard. We ran the imputation model 30 times and combined the results using Rubin’s 
rules.13 Stage-specific survival estimates using the imputed datasets were then compared with 
the corresponding results without imputation (Supplementary Tables 1 & 2).  All analyses were 




Final results are presented by grouped TNM for all countries except Australia and New Zealand 
where TNM data were not collected, and mapped SEER stage for all countries, and stratified by 
histology group. All results relate to imputed stage, unless otherwise noted. For simplicity, we 
used stages I-IV when referring to TNM stage, and ‘localised’, ‘regional’, and ‘distant’ when 
referring to mapped SEER stage. Finally, while we focussed on sex-specific estimates, the 
findings for both sexes combined are presented in Supplementary Figures 2-5 and 
Supplementary Tables 1-10. 
 
RESULTS 
In total, 367,707 patients (93.5%) diagnosed during 2010-2014 were included in the survival 
analyses (Table 1). 280,744 cases (76.4% of eligible cases) were microscopically confirmed, 
either through cytologic examination, histology of primary tumour or of metastasis. The proportion 
with NSCLC ranged between 59% (UK) and 76% (Australia) while the proportion with SCLC was 
largely consistent across all countries at 11-12%, with a slightly larger proportion in Denmark 
(14%) and Norway (16%). The proportion with unspecified cancers ranged from 11% (Denmark) 
to 29% (UK). For the remainder of this report we will comment only on results for NSCLC and 
SCLC cases (n=279,281). 
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Table 1. Characteristics of patients diagnosed with lung cancer during 2010-2014 
  
Australiaº Canada† Denmark Ireland¶ New Zealand Norway 
United 
Kingdom‡ Total 
Number of patients diagnosed during 2010-2014 18,567 90,439 22,828 9,393 10,309 14,538 227,379 393,453 
Exclusions                 
     Diagnosed based on death certificate only (DCO) or autopsy 665 (3.6%) 1,412 (1.6%) 272 (1.2%) 157 (1.7%) 185 (1.8%) 334 (2.3%) 5,080 (2.2%) 8,105 (2.1%) 
     Quality control∆ 48 (0.3%) 5 (0.0%) None None None None 1 (0.0%) 54 (0.0%) 
     Age <15 or >99 years 4 (0.0%) 20 (0.0%) 1 (0.0%) 2 (0.0%) 1 (0.0%) 4 (0.0%) 95 (0.0%) 127 (0.0%) 
     Second or higher order cancers at the same site  89 (0.5%) 1,478 (1.6%) 78 (0.3%) 187 (2.0%) 2 (0.0%) 172 (1.2%) 3,028 (1.3%) 5,034 (1.3%) 
     Cases with inconsistencies in stage information* None 174 (0.2%) 801 (3.5%) 204 (2.2%) None 292 (2.0%) 3,086 (1.4%) 4,557 (1.2%) 
     Neuroendocrine Neoplasms (NENs)◊ 451 (2.4%) 1,846 (2.0%) 629 (2.8%) 270 (2.9%) 181 (1.8%) 371 (2.6%) 4,121 (1.8%) 7,869 (2.0%) 
Total cases eligible for survival analysis 17,310 (93.2%) 85,504 (94.5%) 21,047 (92.2%) 8,573 (91.3%) 9,940 (96.4%) 13,365 (91.9%) 211,968 (93.2%) 367,707 (93.5%) 
% Males 59.1% 51.9% 51.1% 56.6% 52.7% 55.2% 54.4% 53.9% 
Histological subtype                 
     SCLC₸ 1,971 (11.4%) 9,671 (11.3%) 2,991 (14.2%) 1,089 (12.7%) 1,185 (11.9%) 2,097 (15.7%) 24,163 (11.4%) 43,167 (11.7%) 
     NSCLC§ 13,115 (75.8%) 59,969 (70.1%) 15,590 (74.1%) 6,006 (70.1%) 6,619 (66.6%) 9,414 (70.4%) 125,401 (59.2%) 236,114 (64.2%) 
     Other∂ 44 (0.3%) 119 (0.1%) 62 (0.3%) 19 (0.2%) 23 (0.2%) 30 (0.2%) 403 (0.2%) 700 (0.2%) 
     Unspecified₳ 2,180 (12.6%) 15,745 (18.4%) 2,404 (11.4%) 1,459 (17.0%) 2,113 (21.3%) 1,824 (13.6%) 62,001 (29.3%) 87,726 (23.9%) 
† Canadian provinces included: Alberta, British Columbia, New Brunswick, Manitoba, Newfoundland, Nova Scotia, Ontario, Prince Edward Island, and Saskatchewan 
‡ United Kingdom registries included: England, Northern Ireland, Scotland, and Wales 
º Australia registries included: New South Wales  
¶ Ireland (2010-2013) 
∆ Includes: data inconsistencies (invalid age, missing/incomplete dates), tumours with non-malignant behavior, tumours with invalid morphological or topographical codes 
* Stage error or in situ flag 
◊ NENs (ICD-O-3 morphology): 8013 and 8041-8045 (excluding lung cancer), 8150-8158, 8240-8247, 8249, 9091, 8574 
₸ SCLC, small cell lung cancer (ICD-O-3 morphology): 8041-8045 
§ NSCLC, non-small cell lung cancer (ICD-O-3 morphology): 8012, 8014, 8050-8078, 8083, 8084, 8140, 8211, 8230–8231, 8250–8260, 8323, 8480–8490, 8550–8552, 8570–8574, 8576 
∂ Other, specified (ICD-O-3 morphology): 8800-8811, 8830, 8840-8921, 8990, 8991, 9040-9044, 9120-9133, 9150, 9540-9581 
₳ Unspecified (ICD-O-3 morphology): 8000-8005, 8010, 8011 
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Non-Small Cell Lung Carcinoma 
At least 45% of the 236,114 NSCLC cases were diagnosed at the most advanced stage (Stage 
IV for TNM, distant stage for SEER) for males in all countries, with the largest proportion observed 
in New Zealand at 59.8% (Table 2A, Figure 1A). Compared to males, females had a more 
favourable stage distribution in all countries, except New Zealand and Denmark (Table 2B, 
Figure 1A).  
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Table 2A. Number and proportion of male patients with non-small cell lung carcinoma (NSCLC) and small cell lung carcinoma (SCLC) diagnosed 
during 2010-2014 by country and stage at diagnosis (TNM and SEER), before and after imputation 
  TNM stage       Mapped SEER     
    NSCLC   %   SCLC   %     NSCLC   %   SCLC    % 








on   Number 
Median age 
at diagnosis  Observed 
After 
imput
ation   Stage Number 
Median age 
at diagnosis  Observed 
After 
imputation   Number 
Median age at 
diagnosis  Observed 
After 
imputation 
Australiaº All patients                     c 7,786 71 (63-78)       1,132 70 (63-77)     
  Missing                     Missing 820 73 (66-81) 10.5     89 69 (61-77) 7.9   
  I                     Localised 1,419 72 (66-78) 20.4 21.2   86 73 (62-79) 8.2 9.3 
  II                     Regional 1,873 70 (63-77) 26.9 27.0   230 69 (64-75) 22.1 22.0 
  III                     Distant 3,674 70 (62-77) 52.7 51.8   727 70 (63-77) 69.7 68.7 
  IV                                         
Canada† All patients 31,142 70 (63-77)       4,862 68 (61-75)       
All 
patients 31,142 70 (63-77)       4,862 68 (61-75)     
  Missing 1,945 71 (64-78) 6.2     202 69 (63-76) 4.2     Missing 1,686 71 (63-78) 5.4     173 69 (62-75) 3.6   
  I 5,401 71 (65-78) 18.5 19.1   126 74 (66-78) 2.7 3.0   Localised 4,289 71 (65-78) 14.6 15.3   107 74 (68-78) 2.2 2.6 
  II 3,022 71 (64-77) 10.4 10.5   142 69 (63-76) 3.0 3.3   Regional 10,424 71 (64-77) 35.4 35.2   1,157 68 (62-75) 23.8 25.6 
  III 6,137 70 (63-77) 21.0 21.0   984 68 (61-75) 21.1 22.0   Distant 14,743 69 (62-77) 50.1 49.4   3,425 68 (61-75) 70.4 71.7 
  IV 14,637 69 (62-77) 50.1 49.5   3,408 68 (61-75) 73.1 71.8                       
Denmark All patients 8,045 70 (64-76)       1,491 70 (63-76)       
All 
patients 8,045 70 (64-76)       1,491 70 (63-76)     
  Missing 216 72 (64-79) 2.7     40 75 (63-82) 2.7     Missing 102 71 (64-78) 1.3     20 79 (63-83) 1.3   
  I 580 70 (65-76) 7.4 8.0   23 71 (59-74) 1.6 1.6   Localised 1,372 71 (65-77) 17.3 18.2   50 71 (66-75) 3.4 3.3 
  II 1,396 71 (65-77) 17.8 18.5   47 71 (65-76) 3.2 3.1   Regional 2,054 70 (63-76) 25.9 25.7   192 70 (64-77) 13.1 11.6 
  III 1,750 70 (63-77) 22.4 21.3   271 69 (63-75) 18.7 16.6   Distant 4,517 69 (63-76) 56.9 56.1   1,229 70 (63-75) 83.5 85.1 
  IV 4,103 69 (63-76) 52.4 52.2   1,110 70 (63-75) 76.5 78.7                       
Ireland¶ All patients 3,522 70 (63-76)       542 67 (61-74)       
All 
patients 3,522 70 (63-76)       542 67 (61-74)     
  Missing 493 73 (65-79) 14.0     79 70 (62-77) 14.6     Missing 258 72 (65-79) 7.3     36 73 (62-77) 6.6   
  I 286 70 (64-77) 9.4 9.3   9 63 (58-80) 1.9 2.6   Localised 651 71 (64-77) 19.9 20.4   23 63 (57-77) 4.5 5.0 
  II 587 70 (64-76) 19.4 19.0   18 68 (62-78) 3.9 4.2   Regional 1,143 70 (63-77) 35.0 34.0   131 68 (62-74) 25.9 24.9 
  III 865 69 (62-76) 28.6 28.7   110 67 (62-72) 23.8 23.3   Distant 1,470 68 (61-75) 45.0 45.6   352 67 (61-73) 69.6 70.1 
  IV 1,291 68 (61-75) 42.6 43.0   326 67 (61-73) 70.4 69.9                       
New Zealand All patients                     
All 
patients 3,493 70 (63-77)       615 68 (61-75)     
  Missing                     Missing 1,131 72 (65-79) 32.4     144 69 (61-76) 23.4   
  I                     Localised 262 69 (63-74) 11.1 12.3   3 61 (59-83) 0.6 0.6* 
  II                     Regional 558 70 (62-75) 23.6 27.9   71 68 (62-73) 15.1 15.1* 
  III                     Distant 1,542 69 (61-76) 65.3 59.8   397 68 (60-75) 84.3 84.3* 
  IV                                         
Norway All patients 5,286 70 (64-77)       1,068 69 (63-77)       
All 
patients 5,286 69 (63-77)       1,068 69 (63-77)     
  Missing 1,167 71 (64-79) 22.1     330 69 (63-75) 30.9     Missing 113 75 (67-81) 2.1     36 73 (66-81) 3.4   
  I 514 71 (65-77) 12.5 13.4   16 74 (68-77) 2.2 3.0   Localised 1,167 71 (65-77) 22.6 22.0   80 72 (63-78) 7.8 8.0 
  II 810 69 (64-76) 19.7 18.4   46 70 (65-77) 6.2 6.8   Regional 1,717 70 (64-77) 33.2 34.1   271 68 (62-76) 26.3 27.8 
  III 1,017 70 (63-77) 24.7 23.1   186 68 (62-76) 25.2 23.7   Distant 2,289 69 (62-77) 44.2 43.9   681 69 (64-77) 66.0 64.2 
  IV 1,778 69 (63-76) 43.2 45.1   490 70 (64-77) 66.4 66.6                       
United 
Kingdom‡ All patients 71,098 71 (64-78)       12,335 70 (63-76)       
All 
patients 71,098 71 (64-78)       12,335 70 (63-76)     
  Missing 24,093 71 (64-78) 33.9     4,175 70 (63-76) 33.8     Missing 18,958 72 (64-79) 26.7     3,683 70 (63-76) 29.9   
  I 6,285 72 (66-78) 13.4 13.8   179 71 (64-77) 2.2 2.4   Localised 9,563 72 (66-77) 18.3 17.0   258 71 (64-77) 3.0 2.8 
  II 5,330 72 (65-78) 11.3 11.0   259 70 (64-78) 3.2 3.1   Regional 14,356 71 (64-77) 27.5 26.4   1,504 70 (64-76) 17.4 17.0 
  III 11,278 71 (64-77) 24.0 23.6   1,812 69 (63-75) 22.2 22.3   Distant 28,221 70 (63-77) 54.1 56.7   6,890 70 (63-76) 79.6 80.2 
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  IV 24,112 70 (63-77) 51.3 51.6   5,910 70 (63-76) 72.4 72.3                       
† Canadian provinces included: Alberta, British Columbia, New Brunswick, Manitoba, Newfoundland, Nova Scotia, Ontario, Prince Edward Island, and Saskatchewan   
‡ United Kingdom registries included: England, Northern Ireland, Scotland, and Wales 
º Australia registries included: New South Wales  
¶ Ireland: 2010-2013 
* Model did not converge 
 
Table 2B. Number and proportion of female patients with non-small cell lung carcinoma (NSCLC) and small cell lung carcinoma (SCLC) diagnosed 
during 2010-2014 by country and stage at diagnosis (TNM and SEER), before and after imputation 
  TNM stage       Mapped SEER     
    NSCLC   %   SCLC   %     NSCLC   %   SCLC   % 









n   Number 
Median age 
at diagnosis  Observed 
After 
imputati
on   Stage Number 
Median age 
at diagnosis  Observed 
After 
imputation   Number 
Median age at 




Australiaº All patients                    All patients 5,329 69 (62-77)       839 69 (61-76)     
  Missing                    Missing 536 72 (64-81) 10.1     69 72 (64-79) 8.2   
  I                    Localised 1,095 71 (64-77) 22.8 24.9   83 69 (60-76) 10.8 11.5 
  II                    Regional 1,272 69 (62-76) 26.5 26.6   206 69 (60-76) 26.8 25.2 
  III                    Distant 2,426 68 (60-77) 50.6 48.5   481 68 (61-75) 62.5 63.3 
  IV                                        
Canada† 
All 
patients 28,827 69 (62-76)       4,809 69 (61-75)      All patients 28,827 69 (62-76)       4,809 69 (61-75)     
  Missing 1,745 71 (62-79) 6.1     189 70 (63-78) 3.9    Missing 1,534 71 (62-78) 5.3     155 70 (63-77) 3.2   
  I 6,421 70 (63-76) 23.7 25.0   155 72 (63-77) 3.4 3.8  Localised 5,072 70 (63-77) 18.6 19.8   129 71 (63-77) 2.7 3.1 
  II 2,692 70 (62-76) 9.9 10.0   173 70 (64-77) 3.7 4.0  Regional 9,409 69 (62-76) 34.5 34.7   1,438 68 (60-75) 29.9 32.1 
  III 5,250 69 (62-76) 19.4 19.5   1,229 68 (60-74) 26.6 27.5  Distant 12,812 68 (60-76) 46.9 45.5   3,087 69 (61-75) 64.2 64.8 
  IV 12,719 68 (60-76) 47.0 45.5   3,063 69 (61-75) 66.3 64.7                      
Denmark 
All 
patients 7,545 69 (62-76)       1,500 69 (62-76)      All patients 7,545 69 (62-76)       1,500 69 (62-76)     
  Missing 180 74 (67-80) 2.4     44 65 (56-75) 2.9    Missing 74 74 (68-82) 1.0     14 71 (65-77) 0.9   
  I 768 69 (63-76) 10.4 11.8   23 69 (62-76) 1.6 1.9  Localised 1,543 70 (63-76) 20.7 22.5   52 69 (60-76) 3.5 4.0 
  II 1,245 69 (62-76) 16.9 17.6   60 69 (62-76) 4.0 4.2  Regional 1,675 69 (62-76) 22.4 21.9   246 68 (62-75) 16.6 17.0 
  III 1,450 68 (61-74) 19.7 17.9   327 68 (61-74) 21.8 23.1  Distant 4,253 69 (61-76) 56.9 55.6   1,188 69 (62-76) 79.9 79.0 
  IV 3,902 69 (61-76) 53.0 52.7   1,046 69 (62-76) 69.7 70.7                      
Ireland¶ 
All 
patients 2,484 69 (62-76)       547 68 (61-75)      All patients 2,484 69 (62-76)       547 68 (61-75)     
  Missing 310 73 (64-81) 12.5     96 71 (63-78) 17.6    Missing 148 76 (66-82) 6.0     48 72 (60-79) 8.8   
  I 358 69 (62-75) 16.5 16.9   11 65 (57-73) 2.4 2.6  Localised 632 69 (63-77) 27.1 28.4   27 69 (65-75) 5.4 6.2 
  II 433 70 (63-77) 19.9 20.5   33 69 (63-80) 7.3 8.1  Regional 745 69 (62-76) 31.9 31.5   155 69 (62-76) 31.1 30.7 
  III 540 69 (62-76) 24.8 24.8   132 68 (61-75) 29.3 30.3  Distant 959 68 (61-75) 41.1 40.1   317 67 (60-74) 63.5 63.1 




patients                    All patients 3,126 68 (61-75)       570 67 (59-74)     
  Missing                    Missing 954 70 (63-77) 30.5     177 68 (59-73) 31.1   
  I                    Localised 270 68 (62-73) 12.4 13.3   3 72 (67-75) 0.8 0.8* 
  II                    Regional 456 67 (60-73) 21.0 24.4   82 67 (58-74) 20.9 20.9* 
  III                    Distant 1,446 67 (59-75) 66.6 62.3   308 67 (59-74) 78.4 78.4* 
  IV                                        
Norway 
All 
patients 4,128 69 (62-76)       1,029 68 (61-75)      All patients 4,128 68 (61-75)       1,029 68 (61-75)     
  Missing 895 69 (63-77) 21.7     354 68 (62-75) 34.4    Missing 89 69 (64-78) 2.2     29 75 (67-78) 2.8   
  I 589 68 (63-75) 18.2 17.5   26 65 (60-73) 3.9 3.3  Localised 1,067 69 (64-76) 26.4 25.9   85 68 (59-75) 8.5 8.0 
  II 601 69 (63-75) 18.6 17.7   48 65 (59-75) 7.1 6.4  Regional 1,215 69 (62-76) 30.1 31.4   285 67 (60-73) 28.5 30.6 
  III 677 69 (62-76) 20.9 20.4   167 67 (59-73) 24.7 26.1  Distant 1,757 68 (61-76) 43.5 42.6   630 68 (62-75) 63.0 61.4 
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patients 54,303 70 (63-77)       11,828 68 (62-75)      All patients 54,303 70 (63-77)       11,828 68 (62-75)     
  Missing 17,708 71 (63-78) 32.6     3,935 69 (62-76) 33.3    Missing 13,465 71 (64-79) 24.8     3,494 69 (62-76) 29.5   
  I 6,368 71 (64-77) 17.4 18.2   205 70 (63-77) 2.6 2.8  Localised 9,246 70 (64-76) 22.6 21.2   282 70 (63-77) 3.4 3.4 
  II 3,856 71 (64-77) 10.5 10.3   269 69 (63-75) 3.4 3.4  Regional 10,429 70 (63-77) 25.5 24.8   1,615 68 (62-75) 19.4 19.0 
  III 8,002 70 (63-77) 21.9 21.7   2,086 68 (61-75) 26.4 27.0  Distant 21,163 69 (62-77) 51.8 54.0   6,437 68 (62-75) 77.2 77.6 
  IV 18,369 69 (62-77) 50.2 49.9   5,333 69 (62-75) 67.6 66.8             
† Canadian provinces included: Alberta, British Columbia, New Brunswick, Manitoba, Newfoundland, Nova Scotia, Ontario, Prince Edward Island, and Saskatchewan   
‡ United Kingdom registries included: England, Northern Ireland, Scotland, and Wales 
º Australia registries included: New South Wales  
¶ Ireland: 2010-2013 




For all stages combined, the age-standardised 1-year net survival for NSCLC among males was 
highest for Canada (48.1%) and lowest for Ireland (41.8%), New Zealand (41.5%) and the UK 
(40.8%) (Figure 2A, Supplementary Table 11). The 3-year net survival rates showed a similar 
pattern (between 19.7% and 27.1%). For females, the range was slightly wider for 1-year and 3-
year net survival (between 48.3% and 57.8%, and 25.3 and 35.0%, respectively) (Figure 2A, 
Supplementary Table 12).  
 
Sex-specific net survival varied substantially depending on stage at diagnosis, with little 
consistency in the ranking of countries at both 1-year and 3-years after diagnosis (Figure 3A, 
Supplementary Tables 11-12). For example, for males, Australia had the lowest 1-year net 
survival for localised tumours (81.6%), but the highest 1-year net survival for distant tumours 
(25.6%). Nevertheless, we observed that survival for males and females was consistently high 
across all (SEER) stages for Canada, whilst Ireland and the UK reported consistently lower 
survival. 
 
Among males and females, both 1-year and 3-year survival for distant SEER stage was highest 
for Australia and lowest for the UK, respectively. Further, as seen for overall NSCLC, females had 
higher 1-year and 3-year net survival for all stages at diagnosis. Notable sex differences (i.e. 
>10% point difference) were observed at 1-year post diagnosis for regional NSCLC in New 
Zealand (Δ=10.7% point), Ireland (Δ=12.0% point), and Norway (Δ=11.4% point). 
 
Similar differences in stage-specific net survival were observed when using TNM stage (Figure 
4A, Supplemental Tables 11-12). Among the five countries that provided TNM stage, 1-year net 
survival for NSCLC with TNM stages II and III was significantly lower for males in Ireland, at 69.8% 
and 45.3% respectively, and the UK, at 76.3% (TNM stage II only), compared to Denmark (84.4% 
for stage II , 56.0% for stage III ). Amongst cases diagnosed with stage IV disease, 1-year net 
survival was lowest at 18.8% for males in the UK, followed by Ireland (19.8%), Denmark (21.2%), 
Norway (21.8%), and finally Canada (23.6%). As for females, the lowest survival for all stages at 
both 1-year and 3-years post-diagnosis was observed for the UK and Ireland. The largest absolute 
differences in net survival between countries were observed for stages II and III, and there was 
an indication that survival was more homogeneous for stage IV, particularly for 3-year net survival 





Small Cell Lung Carcinoma 
Approximately 70% of SCLC patients were diagnosed with stage IV or distant disease (Table 2A 
and 2B, Figure 1B), although some variation was observed between countries and sexes; for 
example, New Zealand had the largest proportion of patients diagnosed with distant disease at 
84.3% for males and 78.4% for females. Females had a more favourable stage distribution 
compared to males. 
 
One-year net survival ranged for males from 25.0% in New Zealand and the UK to 31.8% in 
Australia, and for females 31.2% in the UK to 39.2% in Canada (Figure 2B, Supplementary 
Tables 13-14). Canada and Norway had the highest 3-year net survival for both males and 
females, though differences between the seven countries were minimal. There were large 
disparities in net survival between sexes, in particular at 1-year after diagnosis, with 1-year net 
survival for females being 6.2 percentage points (UK) to 10.6 percentage points (Canada) higher 
than that observed for males.  
 
Differences by SEER stage in net survival between the seven countries were also found (Figure 
3B, Supplementary Tables 13-14). Among males with localised SCLC, 1-year net survival was 
lower in Australia (58.3%) and Norway (58.6%) than in Canada (82.2%) and Denmark (79.5%). 
For cases with regional and distant disease, males in Denmark had the highest 1-year net survival 
at 63.0% and 24.3%, respectively; whereas for regional disease, 1-year survival was lowest for 
males in Ireland and New Zealand, and Norway and New Zealand had the lowest survival for 
distant cases. Net survival at 3-years among male patients showed similar patterns. For females, 
1-year and 3-year net survival was highest in Denmark for most stages. New Zealand and Norway 
had lower survival for most stages along with Ireland and the UK, though most notable was the 
low survival observed for females with localised stage in Australia (62.8%) at one year post 
diagnosis (Supplementary Table 14).  
 
Net survival by TNM stage is shown in Figure 4B (Supplemental Tables 13-14). In general, 
similar differences in stage-specific net survival were observed when using TNM stage. For 
example, for females, 1-year net survival for stage III SCLC ranged from 49.1% in Ireland to 
56.3% in Canada; the corresponding 3-year net survival ranged from 15.6% in the UK to 24.2% 
in Canada. As with NSCLC, the survival differences among the countries investigated were 




Within country differences 
While it was beyond the scope of this manuscript to explore within-country disparities for NSCLC 
and SCLC survival in detail, the best outcomes in Canada were generally observed for Manitoba 
and New Brunswick while the worst outcomes were observed for Prince Edward Island and Nova 
Scotia, although the differences were not always statistically significant due to low statistical 
power for the latter jurisdictions (Supplemental Tables 6-10, 15-20). In the UK, survival for 
NSCLC and SCLC appeared to be highest in Scotland for early disease stages, with survival at 
advanced stages being generally comparable across the four jurisdictions.   
 
DISCUSSION  
In this study, discrepancies in lung cancer survival were evident across countries by sex, 
histological group and stage, with higher survival observed for Canada and Norway, and lower 
survival in the UK, New Zealand and Ireland. Survival was consistently higher for females (for all 
stage and histological groups) and for NSCLC. Variations in stage distribution and stage-specific 
survival estimates were apparent and may partly explain international survival differences. Net 
survival within stage groups varied across countries whereby survival was consistently higher 
across stages of disease for Canada and Denmark, and consistently lower for Ireland and the 
UK.  
 
A previous study of a similar group of countries reported 1-year net survival among lung cancer 
cases diagnosed from 2004-2007.2 Despite differences in study methods, generally we obtained 
similar results with respect to survival differences by histological group and stage, as well as the 
countries’ rankings. Similar findings were also noted in another study investigating lung cancer 
survival in Europe for 1999-2007, where Ireland and the UK generally exhibited lower survival.15 
Nonetheless, a decade later, we observed improved survival for lung cancer for all countries,8 as 
well as higher stage-specific survival particularly for NSCLC in this study. However, the 
contribution of stage migration to the apparent improvement in stage-specific survival cannot be 
completely ruled out. For example, the migration due to coding stage III to stage IV disease 
resulting from increased sensitivity and utilization of novel imaging techniques, such as positron 
emission tomography. 
 
Our findings show that females generally are diagnosed at an earlier stage and have better 
survival outcomes than men. This is in line with previous studies3-6 evaluating the effect of sex on 
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lung cancer prognosis and several potential reasons for this observation have been proposed. 
Firstly, adenocarcinoma lung cancer is the predominant subtype of NSCLC and is more common 
among females than males. As adenocarcinoma lung cancer is associated with being a never 
smokers16 and having a better response to treatment17, we would expect that females would 
experience better NSCLC survival compared to males because there is a higher proportion of 
these favourable cases.  Secondly, adenocarcinoma that has a wider spectrum of growth rate 
with some being quite indolent is generally diagnosed at earlier stages compared to other 
histological types18, which corresponds with our finding that a higher proportion of females present 
with early stage disease, though this may also be due to more frequent and earlier medical 
consultations. Finally, several studies19-21 have also suggested that female sex may be a positive 
prognostic factor in itself21 22, irrespective of age, stage, period of diagnosis and histological 
groups. Further, mutations in epidermal growth factor receptor have been shown to be more 
prevalent in females, which may lead to survival advantages.23,24  
 
Net survival for SCLC was consistently lower compared to that for NSCLC in all countries. This 
corresponds with the fact that SCLC tends to grow and spread faster than NSCLC, exemplified 
by previous research that found larger proportions of individuals with SCLC compared with 
NSCLC diagnosed at advanced stage or with co-morbid illnesses, which may lead to fewer 
patients being considered for curative treatment.25 For example, in Norway, only 1.7% of patients 
with SCLC received surgery compared to 18.1% of those with any lung cancer in the period 2002-
2011.26 While we observed considerable differences in 1-year net survival across countries for 
SCLC, disparities were much smaller at 3 years, which may be explained by the high fatality rate 
of SCLC regardless of available treatments.27  
 
Disparities observed for NSCLC between countries may partly relate to varying proportions with 
squamous cell carcinoma, large cell carcinoma, and adenocarcinoma, together forming the group 
with NSCLC. For example, for NSCLC, 50% were adenocarcinomas for Canadian males 
compared with 40% for males in the UK with a similar difference for females (62% versus 51% 
respectively). As a result, the UK had a larger proportion of squamous cell carcinomas which are 
associated with lower survival overall compared to adencarcinoma.28 Unfortunately further 
stratification of the NSCLC by finer histological groupings was not possible due to insufficient 
statistical power. Similarly, the UK and New Zealand had larger proportions with NSCLC and 
SCLC diagnosed at later stages compared to other countries suggesting that countries like 
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Canada may detect cancers earlier, although a formal recommendation for lung cancer screening 
was made in Canada after our study period in 2016.29  
 
Although differences in stage distribution will account for some of the survival disparities between 
countries, differences in stage-specific survival were also evident across countries in our study. 
These absolute differences were most pronounced for localised and regional stage disease, and 
may relate to the variability in treatment and management. For example, as surgical resection 
offers the only realistic chance of cure for lung cancer,30 differences in rates of surgery may partly 
explain survival differences in patients with localised and regional lung cancer. Differences in 
prehabilitation prior to lung cancer surgery or age at diagnosis across countries are other factors 
that may explain the observed survival differences.31 For example, the median age of patients 
with NSCLC in the UK was generally higher than that for other countries at each cancer stage. 
Previous studies have shown that patients at older ages are more likely to have comorbid 
conditions, which are known predictors of treatment decisions and poorer outcomes including 
survival.32 Whilst historically only around 9% of NSCLC patients in the UK underwent surgery, the 
current percentage is 18% according to the National Lung Cancer Audit 2018 annual report, which 
is above the national standard.33 Combined with the other improvements in lung cancer care in 
the UK, including recent adoption of immunotherapy and increases in pathological confirmation 
of cancer and overall cancer care33, we expect to see improvements in stage-specific survival in 
the next ICBP iteration.  
 
A strength of our study is that all data are from high-quality population-based cancer registries, 
which were additionally standardised and checked using a predefined protocol. All results were 
validated and interpreted with the input of local experts, including registry experts, epidemiologists 
and clinicians from each country. Yet, a number of limitations should be noted. First, there is still 
a substantial proportion of cases with unknown histology, ranging between 11% and 29% across 
the seven countries. While survival for these cases is typically lower than for cases with known 
histology, the size of this group might have affected survival estimates for SCLC and NSCLC. In 
a complementary paper, we showed that while the proportion of lung cancer cases with unknown 
histology has an impact on survival estimates for “known” histology groups, the inclusion and/or 
reallocation of these individuals does not change international rankings or overall patterns we see 
across countries34. Second, when mapping information from different staging systems, there is 
potential for misclassification, which might have affected the reported stage distributions and 
corresponding survival estimates. When analyses were restricted to cases with both SEER and 
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TNM information, discrepancies in the final summary stage were found for 8% of all cases and 
this affected the estimated survival for localised and regional stage disease only (results not 
shown). Nonetheless, differences in cancer registration practices and staging systems used 
should be taken into account when interpreting the results of this paper.35 Finally, missing 
information on stage at diagnosis presents another potential concern when conducting survival 
comparisons by stage across countries. To some extent, we mitigated the issue of differential 
missingness across countries by running imputation models separately by country (or jurisdiction) 
and by including measures of survival time in the models. In sensitivity analyses, we showed that 
both approaches (with and without imputation) led to very similar results. Yet, there are factors 
that cannot be taken into account in multiple imputation models that may influence missingness 
of stage information such as differences in registration practices36 and this may have affected our 
results. Including information such as comorbidity or performance status may improve the 
imputation and also further our understanding on the causes of survival difference by stage across 
countries. 
 
In conclusion, this study provides more recent estimates of stage-specific lung cancer survival for 
seven high-income countries with comparison for the two main histological types and investigating 
differences by sex. Whilst wide international disparities in lung cancer survival persist, this study 
illustrates the favourable prognosis for NSCLC cases and early stage lung cancers for females. 
It is also evident that differences in stage distribution across sex groups, histological types and 
countries partly explain better lung cancer survival, yet international differences were also 
observed for stage-specific survival suggesting that factors linked to disease treatment and 
management, such as rates of high-quality surgery, utilisation of targeted therapy or rehabilitation 
with increased focus on smoking and physical activity, may be contributing to international 
disparities in lung cancer survival. As the largest disparities were noted for regional stage disease, 
the opportunity for intervention may be greatest for this group. Finally, it is recommended that 
efforts should be made, and resources allocated, to improve the availability and comparability of 
stage data across countries. This will enable further research to understand the reasons behind 
international differences in stage-specific survival, which may fuel policy development and 
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